Literature DB >> 20164036

Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling.

Ewa Lukasiewicz1, Katarzyna Miekus, Jacek Kijowski, Grazyna Drabik, Miroslawa Wilusz, Sylwia Bobis-Wozowicz, Marcin Majka.   

Abstract

Rhabdomyosarcoma (RMS) is a soft tissue sarcoma usually diagnosed in children. In advanced and metastatic stages the prognosis is often poor. RMS cell lines were used for evaluation of the role of MET receptor inhibition on chemotaxis and invasion. In vivo studies were performed using NOD-SCID xenograft model. This study shows that blocking of MET expression has strong influence on metastatic behavior of RMS. MET negative cells possess a reduced potential to migrate and to invade. Downregulation of MET suppressed the ability of RMS cells to populate bone marrow. Inhibition of MET negative tumor cells engraftment into bone marrow was observed. MET negative tumors were also two to four times smaller than their wild type counterparts. Since MET receptor plays a very important role in facilitating metastasis of RMS cells, blocking of HGF-MET axis might be considered as a therapeutic option for RMS patients, at more advanced and metastatic stages.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20164036     DOI: 10.2478/v10042-009-0108-x

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  11 in total

Review 1.  Targeted therapy in bone and soft tissue sarcoma in children and adolescents.

Authors:  Patrick A Thompson; Murali Chintagumpala
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

2.  MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression.

Authors:  Clara Perrone; Silvia Pomella; Matteo Cassandri; Michele Pezzella; Giuseppe Maria Milano; Marta Colletti; Cristina Cossetti; Giulia Pericoli; Angela Di Giannatale; Emmanuel de Billy; Maria Vinci; Stefania Petrini; Francesco Marampon; Concetta Quintarelli; Riccardo Taulli; Josep Roma; Soledad Gallego; Simona Camero; Paolo Mariottini; Manuela Cervelli; Roberta Maestro; Lucio Miele; Biagio De Angelis; Franco Locatelli; Rossella Rota
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

3.  Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

Authors:  Lisa E S Crose; Corinne M Linardic
Journal:  Sarcoma       Date:  2011-01-02

4.  Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.

Authors:  Jinxuan Hou; Jixin Dong; Lijun Sun; Liying Geng; Jing Wang; Jialin Zheng; Yan Li; Julia Bridge; Steven H Hinrichs; Shi-Jian Ding
Journal:  J Transl Med       Date:  2011-05-16       Impact factor: 5.531

5.  MET receptor is a potential therapeutic target in high grade cervical cancer.

Authors:  Katarzyna Miekus; Marta Pawlowska; Małgorzata Sekuła; Grazyna Drabik; Zbigniew Madeja; Dariusz Adamek; Marcin Majka
Journal:  Oncotarget       Date:  2015-04-30

6.  Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors.

Authors:  Marica Peron; Federica Lovisa; Elena Poli; Giuseppe Basso; Paolo Bonvini
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

7.  Multiple Autologous Bone Marrow-Derived CD271+ Mesenchymal Stem Cell Transplantation Overcomes Drug-Resistant Epilepsy in Children.

Authors:  Olga Milczarek; Danuta Jarocha; Anna Starowicz-Filip; Stanislaw Kwiatkowski; Bogna Badyra; Marcin Majka
Journal:  Stem Cells Transl Med       Date:  2017-12-10       Impact factor: 6.940

8.  Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis.

Authors:  Amy D Marshall; Gerard C Grosveld
Journal:  Skelet Muscle       Date:  2012-12-03       Impact factor: 4.912

9.  The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.

Authors:  K Miekus; E Lukasiewicz; D Jarocha; M Sekula; G Drabik; M Majka
Journal:  Cell Death Dis       Date:  2013-01-17       Impact factor: 8.469

10.  Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.

Authors:  Klaudia Skrzypek; Anna Kusienicka; Barbara Szewczyk; Tomasz Adamus; Ewa Lukasiewicz; Katarzyna Miekus; Marcin Majka
Journal:  Oncotarget       Date:  2015-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.